TickerFacts.

Compare

Pacira BioSciences, Inc. vs Emergent BioSolutions Inc. vs Harmony Biosciences Holdings, Inc. vs Opko Health, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearPacira BioSciences, Inc.
PCRX		Emergent BioSolutions Inc.
EBS		Harmony Biosciences Holdings, Inc.
HRMY		Opko Health, Inc.
OPK
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$726.41M$742.90M$868.45M$606.88M
Revenue growth (YoY)+3.6%-28.8%+21.5%-14.9%
Gross margin79.4% (computed)56.1% (computed)77.2%33.9%
Operating margin2.6%13.5%24.0%-19.3%
Net margin1.0%7.1%18.3%-37.2%
Net income$7.03M$52.60M$158.69M-$225.68M
EPS (Diluted)$0.16$0.93$2.71-$0.30
Operating cash flow$151.99M$170.60M$348.20M-$178.54M
Free cash flow$136.66M$156.80M$347.89M-$190.82M
Cash & equivalents$158.54M$205.40M$752.50M$364.41M
Total assets$1.26B$1.32B$1.27B$1.93B
Total liabilities$571.81M$796.00M$401.41M$663.99M
Shareholders' equity$693.11M$522.60M$870.22M$1.27B
Return on year-end equity1.0%10.1%18.2%-17.8%
Shares outstanding41.12M52.10M57.73Mn/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearPacira BioSciences, Inc.Emergent BioSolutions Inc.Harmony Biosciences Holdings, Inc.Opko Health, Inc.
Latest$726.41M
Ended 2025-12-31		$742.90M
Ended 2025-12-31		$868.45M
Ended 2025-12-31		$606.88M
Ended 2025-12-31
1 year earlier$700.97M
Ended 2024-12-31		$1.04B
Ended 2024-12-31		$714.73M
Ended 2024-12-31		$713.14M
Ended 2024-12-31
2 years earlier$674.98M
Ended 2023-12-31		$1.05B
Ended 2023-12-31		$582.02M
Ended 2023-12-31		$863.50M
Ended 2023-12-31
3 years earlier$666.82M
Ended 2022-12-31		$1.12B
Ended 2022-12-31		$437.86M
Ended 2022-12-31		$1.00B
Ended 2022-12-31
4 years earlier$541.53M
Ended 2021-12-31		$1.77B
Ended 2021-12-31		$305.44M
Ended 2021-12-31		$1.77B
Ended 2021-12-31